Holen Sie sich die Stockscreener-App
7.78
2.37%
0.18
Handel nachbörslich:
7.74
-0.04
-0.51%
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
Robbins LLP Urges IBRX Stockholders Who Lost Money Investing in ImmunityBio, Inc. to Contact the Firm for Information About Leading the Class Action - Morningstar
REMINDER: ImmunityBio, Inc. Investors With Significant Losses Must Act By May 26, 2026 - GlobeNewswire
ImmunityBio Inc stock (US45258J1025): Is its immunotherapy pipeline strong enough to unlock biotech - AD HOC NEWS
INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Investor Class ActionHagens Berman - Morningstar
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
ImmunityBio Faces Securities Fraud Lawsuit - National Today
ImmunityBio, Inc. (IBRX) Securities Fraud: Contact Berger Montague To Discuss Your Rights - marketscreener.com
IBRX Investor Alert: ImmunityBio Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Violated FDA Drug Rules: Levi & Korsinsky - PR Newswire
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - GlobeNewswire Inc.
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Lawsuit Alert: Investors who lost money with shares - openPR.com
ImmunityBio, Inc. Class Action Lawsuit: Investors Face May 26, 2026, Deadline - The Globe and Mail
IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline - marketscreener.com
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C. - Toronto Star
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
ImmunityBio founder pushes back after FDA warning letter over Anktiva claims — says ad never aired at all - MSN
ImmunityBio Founder Disputes FDA Warning Over Anktiva Claims - National Today
IBRX stock set to snap 2 days of losses? Anktiva back in focus ahead of COVID-cancer link data - MSN
ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman - PR Newswire
ZSPC Investor News: If You Have Suffered Losses in zSpace Inc. (NASDAQ: ZSPC), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel ... - Caledonian Record
Lowey Dannenberg Notifies ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) ... - Caledonian Record
Lowey Dannenberg Notifies ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm - GlobeNewswire
Kaplan Fox Reminds ImmunityBio, Inc. (NASDAQ: IBRX) Investors of - The National Law Review
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm - Sahm
ImmunityBio, Inc. (IBRX) Posts Strong Preliminary Q1 Sales on ANKTIVA Momentum - Yahoo Finance
Wall Street Bullish on ImmunityBio (IBRX) Since the Announcement of New Findings From QUILT-3.055 Study - MSN
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - GlobeNewswire Inc.
IBRX Investors Eligible to Lead Fraud Lawsuit - National Today
IBRX Stock Set To Snap 2 Days Of Losses? Anktiva Back In Focus Ahead Of COVID-Cancer Link Data - Stocktwits
IBRX Stock In Spotlight: ImmunityBio Guides For 168% Revenue Surge In Q1 On ANKTIVA Momentum - Stocktwits
Press releases provided by CNW - Techaeris
New ImmunityBio timeline emerges - observertoday.com
Investors with Substantial Losses Have Opportunity to Lead ImmunityBio Class Action Lawsuit - National Today
Robbins Geller Announces ImmunityBio Investor Lawsuit Deadline - National Today
IBRX SEC FilingsImmunitybio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with - GlobeNewswire
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - NewMediaWire
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results - Yahoo Finance
IBRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Business Wire
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
IBRX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ImmunityBio, ... - Bluefield Daily Telegraph
IBRX Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
NK Cell Therapy Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Amgen, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Artiva Biotherap - Barchart.com
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Berger Montague PC Investigating Claims on Behalf of ImmunityBio, Inc. (IBRX) Investors After Class Action Filing - marketscreener.com
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities - BioSpace
IBRX stock in spotlight: ImmunityBio guides for 168% revenue surge in Q1 on ANKTIVA momentum - MSN
ImmunityBio Reports Record Q1 2026 Revenue - National Today
Why Is ImmunityBio Stock Rallying Thursday?ImmunityBio (NASDAQ:IBRX) - Benzinga
ImmunityBio, Inc. Reports Preliminary Revenue Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ImmunityBio Stock Climbs 7% as Record $44M Q1 Revenue from ANKTIVA Fuels Biotech Rally - International Business Times Australia
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):